Prof. dr. H.J. (Josef) Vormoor

Specialisme / subspecialisme: kindergeneeskunde/kinderoncologie

Kennis en ervaring

• 2018-heden: Hoofd Afdeling Hemato-oncologie, Prinses Maxima Centrum, Utrecht
• 2018-2023: Visiting Professor, Universiteit Newcastle
• 2013-2017: Directeur, Northern Institute for Cancer Research, Universiteit Newcastle
• 2007-2018: Sir James Spence Professor of Child Health, Universiteit Newcastle
• 2006-2018: Kinderoncoloog, Great North Children’s Hospital, Groot-Britannië
• 1999-2005: Kinderoncoloog, Universitair Medisch Centrum Münster, Duitsland

Promotie

• 1990, Doktor der Medizin (Research MD), “The prognostic significance of Auer rods in childhood AML".

• 1995-1999: AIOS in kindergeneeskunde, Kinderziekenhuis, Universitair Medisch Centrum Münster, Duitsland (inclusief 3 maanden stamcel transplantatie aan het Fred Hutchinson Cancer Center in Seattle, VS)
• 1992-1994: Postdoctoraal onderzoeker, Hospital for Sick Children Toronto, Canada
• 1991: Militaire dienstplicht als officier geneeskundige dienst, Duitse Marine
• 1989-1990: ANIOS (“Arzt im Praktikum”), Kinderziekenhuis, Universitair Medisch Centrum Münster, Duitsland

• 2018, RUNX1/ETO directly targets Cyclin D2 compelling cell cycle progression and leukemic propagation, doi: 
• 2018, Epidemiology and Biology of Relapse after Stem Cell Transplantation, doi: 10.1038/s41409-018-0171-z. 
• 2018, Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies. doi: 10.2217/fon-2018-0121. 
• 2018, Allogeneic hematopoietic cell transplantation in Farber disease, doi: 10.1007/s10545-018-0171-6. 
• 2017, The MLL recombinome of acute leukemias in 2017. doi: 10.1038/leu.2017.213.  2017, From Class Waivers to Precision Medicine in Paediatric Oncology, doi: 10.1016/S1470-2045(17)30442-4. 
• 2017, Early phase clinical trials of anticancer agents in children and adolescents: an Innovative Therapies for Children with Cancer (ITCC) position paper, doi: 10.1038/nrclinonc.2017.59. 
• 2017, Abundant and equipotent founder cells establish and maintain acute lymphoblastic leukaemia, doi: 10.1038/leu.2017.140. 
• 2017, A population pharmacokinetic model of AT9283 in adults and children to predict the maximum tolerated dose in children with leukaemia, doi: 10.1111/bcp.13260.

Contactgegevens